What is the difference between CJC-1295 with and without DAC?

CJC-1295 with DAC binds to albumin and has a half-life of about 6-8 days (Teichman et al., 2006). Under continuous DAC stimulation, mean and trough GH rise while pulse frequency and magnitude are preserved (Ionescu and Frohman, 2006), so it raises baseline GH rather than abolishing pulsatility. The no-DAC form (Mod GRF 1-29) lacks that albumin-binding linker and is therefore much shorter-acting. Direct human pharmacokinetic data on the no-DAC form specifically are limited.

Is "Mod GRF 1-29" the same molecule as the CJC-1295 in this combination?

Yes. "Mod GRF 1-29" is an alternative name some suppliers use for CJC-1295 without DAC, the same 29-amino-acid GHRH analogue described above. The CJC-1295 in this combination is the short-acting no-DAC form, not the long-acting DAC variant that was studied in the Teichman et al. human trial.

Why are CJC-1295 and Ipamorelin combined?

The two act through different receptors (the GHRH receptor and the ghrelin receptor GHS-R1a), so combining them is a mechanistic rationale for a complementary GH signal. GHRH-plus-GHRP synergy is a long-studied phenomenon in this class of research (for example Bowers et al., 1991; Veldhuis and Bowers, 2009), but that work used agents such as GHRH and GHRP-2, not this exact blend, and did not measure a combination-versus-single-agent multiplier for CJC-1295/Ipamorelin. Controlled studies of the specific combination are lacking, so the synergy is a pharmacological expectation rather than a proven result for this blend.

Why is Ipamorelin considered more selective than other GHRPs?

In the Raun et al. (1998) animal studies (rats and conscious swine), Ipamorelin stimulated GH without significantly raising cortisol or prolactin, whereas GHRP-6 and GHRP-2 did at comparable GH-stimulating doses. This selectivity is a preclinical finding; human endocrine-selectivity data for Ipamorelin remain limited.

Is CJC-1295/Ipamorelin the same as human growth hormone (HGH)?

No. CJC-1295 and Ipamorelin are growth hormone secretagogues: they act on the pituitary to stimulate release of the body's own growth hormone, via the GHRH receptor and GHS-R1a respectively. Neither peptide contains or is chemically identical to growth hormone itself, which is a much larger 191-amino-acid protein and a separately regulated substance.

How does the CJC-1295/Ipamorelin combination compare to Sermorelin?

Sermorelin is an earlier, unmodified GHRH(1-29) analogue with a very short half-life and none of the DPP-4-resistant substitutions that extend CJC-1295's activity. Sermorelin engages only the GHRH receptor pathway, so it does not add the GHS-R1a signalling that Ipamorelin contributes here. The two are mechanistically distinct research tools rather than interchangeable options.

Are CJC-1295 and Ipamorelin approved medications?

Neither peptide holds an EU marketing authorisation as a medicinal product. This shop supplies both strictly as research materials, not as medicinal products or products for human consumption.

Is it legal to purchase CJC-1295 and Ipamorelin as research chemicals in the EU?

Neither peptide holds an EU marketing authorisation as a medicinal product. Classification and sale requirements are jurisdiction-specific and may depend on product presentation, intended use and national law, and each member state's implementation of EU medicinal-products law can treat a substance as a medicine based on its physiological function regardless of a "research use only" label. We sell strictly for laboratory research and not for human consumption; this article cannot give legal advice, and buyers should obtain qualified advice for the relevant jurisdiction.

Are CJC-1295 and Ipamorelin on the WADA prohibited list?

In general, yes. Growth hormone releasing factors and growth hormone secretagogues, categories that name CJC-1295 and Ipamorelin in recent World Anti-Doping Agency Prohibited Lists, fall under the S2 peptide-hormone category, prohibited both in and out of competition. This is a sport anti-doping classification, separate from the question of whether purchasing or possessing the research material is lawful in a given country.

Can the purity of this specific CJC-1295/Ipamorelin blend be independently verified?

Yes. This blend carries a Liquilabs report (Prague, batch LYO-0260) that the shop commissioned independently, separately from the routine manufacturer-sourced certificates, alongside a community-submitted result and a manufacturer certificate. The Liquilabs report includes a direct verification link so the result can be checked with the lab itself. The current certificates are listed on our lab-reports page at /coa.

What side effects were reported in the published CJC-1295 and Ipamorelin studies?

The Teichman et al. (2006) trial studied the DAC form of CJC-1295 and reported no serious adverse reactions, with mild effects such as injection-site reactions and headache; it did not report water retention as an outcome. Ipamorelin is generally described as well tolerated, with its main distinguishing feature being selectivity (no significant cortisol or prolactin rise in animal studies). No direct safety trial exists for this no-DAC blend, so these readouts come from short studies of related molecules rather than from the exact product.

Why might a reconstituted CJC-1295/Ipamorelin solution look cloudy?

Peptide blends can look hazy immediately after reconstitution as the powder dissolves. Visual clarity alone cannot confirm identity, purity or sterility, and it cannot rule out a defect. If a solution stays cloudy, or turns cloudy after being clear, document the solvent used, the timing and the batch, keep the material out of any experiment, and contact the supplier so the specific batch can be investigated rather than relying on a visual judgement.

Does research on this combination show any effect on sleep architecture?

Growth hormone secretion is known to concentrate during slow-wave (deep) sleep, and GHRH-analogue and GHRP research has examined this GH-sleep relationship more broadly. No controlled human trial of the CJC-1295/Ipamorelin combination specifically has measured sleep architecture as an endpoint, so any link for this exact blend is extrapolated from general GH-axis physiology rather than direct trial data.

Does raising GH and IGF-1 with this combination affect blood glucose or insulin sensitivity?

Growth hormone is a well-established counter-regulatory hormone that can reduce insulin sensitivity and raise fasting glucose at pharmacological levels, while IGF-1 has some independent insulin-sensitising action, so the net direction depends on dose and duration. No dedicated glucose or insulin-sensitivity trial exists for the CJC-1295/Ipamorelin combination specifically. This is an evidence gap to note rather than a confirmed effect of the blend.

Does Ipamorelin's action on the ghrelin receptor affect appetite?

Ipamorelin acts on GHS-R1a, the same receptor that mediates ghrelin's hunger-stimulating effect, so a mechanistic link to appetite is plausible. Raun et al. (1998) measured cortisol, ACTH, prolactin, FSH, LH and TSH selectivity, not food intake, so dedicated appetite-outcome data for Ipamorelin are limited and should not be assumed either way.

Does the GH-releasing effect diminish with repeated, continuous use?

Dedicated long-duration human data are not available; the longest published CJC-1295 trial covered only 28 to 49 days. Receptor desensitisation under continuous agonist exposure is a recognised concern for this receptor class in the broader pharmacology literature, but whether or to what degree it applies to Ipamorelin over extended use has not been established by a controlled trial.

How should the combination be stored and handled?

Keep the lyophilised (freeze-dried) peptide cold, ideally frozen, and protected from light and repeated freeze-thaw cycles. Bacteriostatic water is a laboratory reconstitution reagent, not a stability guarantee: there is no validated batch-specific study defining a fixed shelf-life for the reconstituted blend, so treat a reconstituted vial as a short-lived working solution, keep it refrigerated, and rely on the batch documentation rather than a fixed number of weeks.

CJC-1295/Ipamorelin Combination: Research Overview and Background

The combination of CJC-1295 and Ipamorelin is among the most frequently discussed peptide stacks in GH research. Both peptides stimulate growth hormone release, but through different receptor systems. This complementary mechanism is the rationale often given for pairing them; controlled studies of this exact blend, however, are lacking, and most of the evidence below comes from the individual peptides or from related GHRH-plus-GHRP research.

This article summarises the available data: mechanisms of action, pharmacokinetic differences, synergy data and the safety profiles of both peptides.

For research purposes only

This text provides a scientific overview. It does not constitute medical advice and does not replace consultation with a physician. Neither peptide holds an EU marketing authorisation as a medicinal product.

CJC-1295 (No-DAC)/Ipamorelingrowth

2-in-1 growth hormone blend: CJC-1295 no-DAC (Modified GRF 1-29, 5 mg) + Ipamorelin (5 mg) combined in one vial. The CJC-1295 component is the short-acting no-DAC variant (about 30 minute half-life), not the long-acting DAC form. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses.

CJC-1295: GHRH Analogue with Extended Duration

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It consists of the first 29 amino acids of natural GHRH with four amino acid substitutions that confer resistance to degradation by dipeptidyl peptidase-4 (DPP-4).

With and Without DAC

A key practical distinction concerns the variant:

CJC-1295 with DAC (Drug Affinity Complex): The DAC component binds to albumin in the blood, extending the half-life to approximately 6-8 days (Teichman et al., 2006). A single injection can elevate GH levels for several days.
CJC-1295 without DAC (also called Mod GRF 1-29): This form lacks the albumin-binding linker and is therefore much shorter-acting. The rationale offered for the no-DAC form is that faster clearance lets GH return toward baseline between exposures, which is expected to keep the signal closer to the body's own pulsatile pattern. Direct human pharmacokinetic data on the no-DAC form specifically are limited, so this remains a mechanistic expectation rather than a figure established by an equivalent published trial.

Clinical Data

Teichman et al. (2006) published the key clinical study on CJC-1295 with DAC in the Journal of Clinical Endocrinology & Metabolism. In this randomised, placebo-controlled, double-blind study of healthy adults (ages 21-61), a single subcutaneous injection produced:

Dose-dependent GH increases of 2- to 10-fold for 6 days or longer
IGF-1 increases of 1.5- to 3-fold for 9-11 days
Estimated half-life: 5.8-8.1 days
Evidence of a cumulative effect with repeated dosing

The authors described the administration as safe and relatively well tolerated, particularly at doses of 30 or 60 mcg/kg. The most frequently reported adverse events were injection-site reactions; headache, diarrhea and flushing were also observed, with occasional transient mild hypotension, primarily at higher studied doses. No serious adverse reactions were reported.

Ipamorelin: Selective Ghrelin Receptor Agonist

Ipamorelin is a pentapeptide that acts on the ghrelin receptor (GHS-R1a) of somatotroph cells in the pituitary gland. It belongs to the Growth Hormone Releasing Peptide (GHRP) class but differs from older members through a significantly more selective profile.

Selectivity as a Distinguishing Feature

Raun et al. (1998) described Ipamorelin in the European Journal of Endocrinology as the "first selective growth hormone secretagogue". These characterisations come from animal models (rats and conscious swine), so they describe the compound's preclinical pharmacology rather than a confirmed human endocrine profile. The key observations reported were:

Ipamorelin released GH without significantly raising ACTH or cortisol above GHRH control levels
Even at doses exceeding 200-fold the ED50 for GH release, cortisol levels remained stable
No significant effect on FSH, LH, prolactin or TSH

For comparison: in the same class of studies, GHRP-6 and GHRP-2 produced measurable increases in ACTH and cortisol at equivalent GH-stimulating doses. Human endocrine-selectivity data for Ipamorelin remain limited.

Why selectivity matters

In GH research, it is often useful to stimulate the growth hormone axis without simultaneously activating the stress axis (HPA axis). In the Raun et al. animal studies, Ipamorelin raised GH without a significant cortisol rise, which is why it is often discussed in this context. Whether the same separation holds in humans has not been established by equivalent clinical data.

The Synergy: GHRH + GHRP

Combining a GHRH analogue with a GHRP is not a new concept. Bowers et al. described as early as 1991 in Endocrinology that GHRP stimulates GH release through an independent, complementary mechanism - separate from the GHRH receptor and independent of opiate receptors.

Two Separate Signalling Pathways

The synergistic effect arises from simultaneous activation of two different receptor systems:

GHRH receptor (activated by CJC-1295): Stimulates the cAMP signalling cascade in somatotroph cells
GHS-R1a (activated by Ipamorelin): Stimulates the phospholipase C cascade and intracellular calcium release

These separate intracellular signalling pathways converge at GH secretion. As a class-level mechanistic rationale, activating both is expected to drive a larger GH response than either pathway alone, though this is a pharmacological expectation rather than a measured result for the CJC-1295 plus Ipamorelin blend.

What the Synergy Research Actually Tested

Veldhuis and Bowers (2009) infused GHRH and GHRP-2 simultaneously in healthy men and examined which factors (age, abdominal-visceral fat, sex steroids, IGF-1) determine the strength of the resulting GHRH-GHRP synergy. Important context for reading that study:

It used GHRH and GHRP-2, not CJC-1295, not Ipamorelin, and not this exact blend
Its design evoked the combined response and studied its determinants; it did not run individual-agent comparison arms to produce a clean combination-versus-monotherapy multiplier
Age and abdominal-visceral fat correlated negatively with synergy, while IGF-1 and IGFBP-3 correlated positively

So the synergy concept is well grounded in GHRH-plus-GHRP research, but a specific numerical multiplier for the CJC-1295/Ipamorelin combination cannot be drawn from these data. Transferability rests on shared receptor pharmacology, not on a trial of this product.

DAC or No DAC: What Matters for Research?

The choice of CJC-1295 variant has direct consequences for research design:

Parameter	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
Half-life	6-8 days (Teichman et al.)	Much shorter (no albumin linker)
Duration of exposure	Days per administration	Brief per administration
Design rationale	Sustained GH drive	Signal closer to the body's own pulsatile pattern

Half-life

CJC-1295 with DAC: 6-8 days (Teichman et al.)
CJC-1295 without DAC (Mod GRF 1-29): Much shorter (no albumin linker)

Duration of exposure

CJC-1295 with DAC: Days per administration
CJC-1295 without DAC (Mod GRF 1-29): Brief per administration

Design rationale

CJC-1295 with DAC: Sustained GH drive
CJC-1295 without DAC (Mod GRF 1-29): Signal closer to the body's own pulsatile pattern

A common assumption is that the DAC form flattens GH into a constant, non-physiological elevation. The direct human data complicate that picture: Ionescu and Frohman (2006) reported that under continuous CJC-1295 DAC stimulation, mean and trough GH rose but the pulse frequency and magnitude of GH secretion were preserved, with endogenous somatostatin regulation apparently still functional. In other words, the DAC form increases baseline GH while pulsatility persists, rather than simply abolishing it. The no-DAC form is chosen mainly for its shorter action, not because a head-to-head human trial has shown it produces a more physiological profile than DAC.

Safety Profile

CJC-1295

The Teichman et al. (2006) trial studied the DAC form of CJC-1295 and reported no serious adverse reactions across the studied dose ranges, with the compound described as safe and relatively well tolerated at 30-60 mcg/kg. The most frequently reported adverse events were injection-site reactions, with headache, diarrhea, flushing and occasional transient mild hypotension also noted, primarily at higher studied doses. This safety readout applies to the DAC molecule in a short study; it does not establish a safety profile for the no-DAC form supplied here, for which no equivalent human trial exists.

Ipamorelin

Ipamorelin is generally described in the literature as well tolerated. Its distinguishing preclinical feature is selectivity: in the Raun et al. (1998) animal studies it stimulated GH without significantly raising cortisol or prolactin, unlike older GHRPs. There is no dedicated long-term human safety trial of Ipamorelin, so any tolerability characterisation is drawn from short studies and preclinical work rather than large controlled data.

Limited long-term data

Long-term safety data for both peptides are limited. The available clinical studies had short durations (28-49 days for CJC-1295). Neither CJC-1295 nor Ipamorelin holds an EU marketing authorisation as a medicinal product.

Summary of Research

The CJC-1295/Ipamorelin combination utilises the complementary receptor pharmacology of GHRH and GHRP signalling pathways. The data support the following key points:

CJC-1295 with DAC extended GHRH receptor activation and increased GH and IGF-1 in a dose-dependent manner in a clinical study (Teichman et al., 2006); the no-DAC form supplied here works through the same receptor but has not been tested in an equivalent trial
In animal studies, Ipamorelin showed high GHRP selectivity with minimal impact on cortisol and prolactin (Raun et al., 1998); equivalent human endocrine-selectivity data are limited
GHRH-plus-GHRP pairing is a well-studied class-level synergy, but the supporting research (Veldhuis and Bowers, 2009) used GHRH plus GHRP-2, not CJC-1295, Ipamorelin, or this blend, and reported no combination-versus-monotherapy multiplier
The Teichman trial evaluated CJC-1295 DAC and Raun supplied preclinical Ipamorelin selectivity data; no equivalent safety study has established a safety profile for the no-DAC blend supplied here

Research in this area remains active, but long-term data and large randomised trials on the exact combination are lacking. The cited publications describe the individual peptides and the general receptor pharmacology rather than this specific blend.

Frequently Asked Questions

Order CJC-1295/Ipamorelin